Complimentary Subscription of Drug Safety Monitor, Including Exclusive Reviews of New and Emerging Drugs, Offered to Managed Care and Media Organizations

Share Article

Market-leading comparative safety research reviews of new drugs vs. current market standards, FDA safety communications and warnings, contextual commentary on drug safety issues powered by Advera Health Analytics

News Image
Our goal is to make drug safety data transparency the norm in the healthcare community.

Advera Health Analytics, Inc. is offering its exclusive Drug Safety Monitor (DSM) at no charge to qualified Managed Care Organizations (MCOs) in order to provide health plans, payers, systems, and hospitals with the ability to incorporate drug safety insight and analysis into their decision making process. In addition, the DSM is also being offered to healthcare media organizations to serve as an independent, unbiased resource and research tool for their pharma industry reporting.

The Drug Safety Monitor helps MCOs incorporate safety data and comparative safety research into P&T decisions, daily pharmacy workflows, and drug price negotiations.

It includes safety reviews for new and soon-to-be launched drugs vs. current market standards, deep dives into FDA communications and warnings, and contextual commentary on other drug safety issues, as well as comparative analyses. Using data and analytics from Adverse Events Explorer, Advera Health’s web-based application that provides standardized and sourced data on post approval drug side effects from FAERS and proprietary data via Freedom of Information Act (FOIA) requests, the DSM is timed to daily current events, and is published as frequently as necessary to bring expert insight to the most current drug news events.

Recent Drug Safety Monitor headlines include:

  • SSRI: RxSignal Identifies Birth Defects 5 Years Prior to FDA Action – October 8
  • Chemotherapy-Induced Nausea and Vomiting: Safety Comparison of Varubi vs. Emend – September 28
  • Type 2 Diabetes Mellitus: Safety Comparison of Synjardy vs. Other SGLT2 Inhibitors – September 24
  • Safety Comparison of Hypoactive Sexual Desire Disorder Treatment, Addyi vs. Serotonin Agonist, Viibryd – September 9

“Our goal is to make drug safety data transparency the norm in the healthcare community,” Advera Health President Brian M. Overstreet explained. “We’re offering the Drug Safety Monitor free so MCOs can see not only the context behind the latest drug safety news, but also how with analysis this news is turned into actionable drug safety information.”

To obtain a free subscription to the Advera Health Drug Safety Monitor click here:

Advera Health Analytics is a health informatics company that improves patient safety and reduces systemic healthcare costs through the comprehensive analysis of real world outcomes data. Advera Health Analytics makes these data accessible, actionable, and predictable. For more information visit – and connect with us on LinkedIn, Facebook and Twitter.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brenda Nashawaty

Sharon Miller
Visit website